Media Doctor Canada
Follow us on Twitter








"New medication approved for gastrointestinal tumours"

Medical Post

Source: Medical Post

Published: 04 Aug 2022

Category: Pharmaceutical

Rating: (4 stars)

what they said (Hover the mouse cursor over underlined words for more info)

Health Canada has approved Sutent (sunitinib) capsules to treat GIST for patients who have failed imatinib mesylate treatment due to resistance or intolerance.
Gastrointestinal stromal tumours (or GIST) represent a rare, extremely hard-to-treat type of stomach and intestinal cancer. For newly diagnosed patients, the primary treatment option is surgery, and after surgery, GIST patients with advanced disease receive Gleevec (imatinib), currently the standard of medical care.
For many patients, Gleevec works well-for a time. However, most GI stromal tumours develop resistance to Gleevec after two years of therapy (and often before); sunitinib can then provide life-extending second-line treatment. One phase III study of Gleevec-resistant gastrointestinal stromal tumours was ended in January 2005, earlier than planned, so impressive was the efficacy data for Sutent

The original article can found in the Media Doctor archives.

how did it rate? (more information)

Criteria Rating
Total Score 8 of 10
Availability of Treatment Satisfactory (?)
Novelty of Treatment Satisfactory (?)
Disease Mongering Satisfactory (?)
Treatment Options Satisfactory (?)
Costs of Treatment Not Satisfactory (?)
Evidence Satisfactory (?)
Quantification of Benefits of Treatment Satisfactory (?)
Harms of Treatment Satisfactory (?)
Sources of Information Not Satisfactory (?)
Relies on Press Release Not Applicable
Quantification of Harms of Treatment Satisfactory (?)

what we said (Hover the mouse cursor over underlined words for more info)

This article is relatively complete in discussing the evidence, the benefits and the harms related to this new treatment for gastrointestinal tumours.

While the story mentions that "treatment-related tumour hemorrhaging was also observed in patients receiving Sutent" we get no sense of how often this happens compared to patients treated with placebo.

Sadly, the issues of cost-efficiency and provincial funding are not mentioned.

public forum

There are currently no comments on this article.

voice your opinion in the forum

  • All comments and feedback submitted to Media Doctor are subject to editorial approval before being made viewable by the public. It may take up to a week for your comments to be approved. Additionally, no response will be given to questions posed in public comments. Media Doctor does not provide medical advice, or answers to medical questions posed by the public.
  • If you provide your email address it will not be displayed to the general public.
  • Comments may be edited by Media Doctor to remove defamatory or sensitive statements, and brand names.
  • Required fields are marked with an asterisk (*).
Name: *
Comments: *
Copyright © Media Doctor Canada